Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue

Gynecologic Oncology
K van BesienJ J Kavanagh

Abstract

Patients with chemotherapy-refractory gestational trophoblastic disease and brain metastasis are considered to have a very poor prognosis. We present the case of a patient who had failed several chemotherapeutic regimens. Despite transient responses to chemotherapy, she had not achieved a complete remission in 3 years, and had developed systemic disease and recurrent brain metastasis. She was treated with four cycles of high-dose ifosfamide, carboplatin, and etoposide with blood progenitor cell support. She tolerated this regimen well and has obtained a complete remission that is ongoing for 12 months.

References

Jul 1, 1972·The Journal of Clinical Investigation·P W Sullivan, S E Salmon
Oct 1, 1980·The American Journal of Medicine·E Frei, G P Canellos
Dec 1, 1980·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R Demicheli
Jul 1, 1996·Anti-cancer Drugs·W TermrungruanglertJ J Kavanagh

❮ Previous
Next ❯

Citations

Feb 9, 2012·Chemotherapy Research and Practice·Taymaa MayRoss S Berkowitz
Aug 21, 2002·Journal of Neurosurgery·Adam N MamelakXuedong Wang
Jan 17, 2012·Hematology/oncology Clinics of North America·Donald Peter Goldstein, Ross S Berkowitz
Nov 29, 2005·Obstetrics and Gynecology Clinics of North America·Harriet O SmithLaurence A Cole
Mar 18, 1999·Hematology/oncology Clinics of North America·E S NewlandsR A Fisher
May 3, 2005·Gynecologic Oncology·John R Lurain, Bahareh Nejad
Nov 5, 2003·Expert Opinion on Pharmacotherapy·John R Lurain
Mar 22, 2005·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·J J YangX R Wan
Oct 15, 2008·Gynecologic Oncology·Ross S Berkowitz, Donald P Goldstein
Aug 24, 2013·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Benedict B Benigno
Oct 16, 2004·Current Oncology Reports·Naveed SarwarMichael J Seckl
Sep 1, 2007·Current Opinion in Oncology·Sarah Ngan, Michael J Seckl
Oct 21, 2010·Expert Opinion on Pharmacotherapy·Noah RodriguezRoss S Berkowitz
Nov 7, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Nadeem R Abu-RustumJillian Scavone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.